Teratogens as anti-cancer drugs
Teratogens as anti-cancer drugs
复制标题
DOI：
10.4161/cc.4.11.2208
复制
发表时间：
2005-11-01
期刊：
影响因子：
4.3
通讯作者：
Blagosklonny, MV
中科院分区：
文献类型：
--
作者：
Blagosklonny, MV
大多数抗癌药物都是致畸药物，仅仅是因为它们针对重要的细胞功能。相反，一些植物会产生故意针对胚胎信号通路的试剂，如果怀孕的动物吃了这些植物，恰恰是为了导致出生缺陷。环丙胺是一种由开花植物产生的致畸物质，它抑制HH/Gli途径，导致发育缺陷，如睫状花眼(面部中部有一只眼睛)。从理论上讲，选择性致畸剂可以抑制重新激活胚胎通路的癌细胞，而不会影响大多数正常细胞。我讨论了致畸剂在癌症治疗中的潜力(和局限性)，将从妊娠呕吐、胚胎发育途径和有毒植物到抗癌致畸剂的作用机制及其与选择性较低的细胞毒剂的组合等不同主题联系起来。
Most anticancer drugs are teratogens, merely because they target vital cellular functions. Conversely, some plants produce agents that intentionally target embryonic signaling pathways, precisely to cause birth defects if pregnant animals eat such plants. Cyclopamine, a teratogen produced by a flowering plant, inhibits the Hh/Gli pathway, causing developmental defects such as cyclopia ( one eye in the middle of the face). In theory, selective teratogens may suppress cancer cells that reactivate embryonic pathways, while sparing most normal cells. I discuss the potential ( and limits) of teratogens in cancer therapy, linking diverse topics from morning sickness of pregnancy, embryonic pathways and poisonous plants to the mechanism of action of anticancer teratogens and their combinations with less selective cytotoxic agents.